Vaccine-induced Immunity in Immunocompromised Patients
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals. In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.
Sponsor: University of Cologne
You may qualify if…
- ✓ Signed informed consent form
- ✓ Patients with immunosuppression either by treatment or underlying diseases
- ✓ Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations
- ✓ Age of 18 years or older
You may not qualify if…
- ✕ Patients unwilling/ineligible for vaccination under current recommendations
Source: ClinicalTrials.gov · NCT06612515 · last updated 2026-05-12